Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (June 2024)
32 slides from Inspiremd's investor presentation, Jun 13, 2024
Slide 1: CGuard EPS Carotid Stent Platform: Sustained Embolic Protection
CGuard EPS Carotid Stent Platfo! Sustained Embolic Protection } INSPIREM Nasdaq: NSPR
Slide 2: Disclaimers
Disclaimers Forward Looking Statement This presentation contains “forward-looking statements.” Such statements may be preceded by the words “intends,” "may," "will," "plans," "expects," "anticipates," "projects," “predicts,” "estimates," "aims," "believes," “hopes,” "potential or similar words. For
Slide 3: Investment Highlights: Poised to Transform the Carotid Intervention Market
CGuard EPS Stent Platform Utilizing Proprietary MicroNet™ Technology Highly differentiated platform for treatment of carotid artery disease and stroke prevention Unmatched Clinical Outcomes (Short- and Long-Term) Ten clinical trials completed with >2,000 patients presented or published including US
Slide 4: Cardiovascular Procedures: The Endovascular Revolution is Nearly Complete
Cardiovascular Procedures: The Endovascular Revolution is Nearly Complete CEREBRAL CORONARY THORACIC/ABDOMINAL PERIPHERAL CAROTID ARTERY ANEURYSMS: ARTERY DISEASE AORTIC ANEURYSMS ARTERIAL DISEASE DISEASE [AWAITING CONVERSION TO ENDO 30% ae 23% ee 35% en 19% —_ 29)dV0* Market potenti for ‘pen to end
Slide 5: Potential Multi-Billion Dollar Market Opportunity
Potential Multi-Billion Dollar Market Opportunity MicroNet™ covered CGuard™ stent platform could become the new gold standard Carotid procedures today are (erect met che © Current Treated Global Market: primarily surgical mostly minimally invasive with CGuard™ > $1.3 billion 407K Global procedures (
Slide 6: Long-Term Stent Performance is the Cornerstone of Our Focus
Long-Term Stent Performance is the Cornerstone of Our Focus Delivery Platform Agnostic CGuard EPS v Well-positioned to capitalize on the ongoing paradigm shift toward a “stent first” approach and away from surgery v Agnostic to stent delivery approach (TCAR vs. CAS) INSPIREMD
Slide 7: PROBLEM: Approximately 2/3 of neurovascular events occur after the carotid procedure
PROBLEM: Approximately 2/3 of neurovascular events (stroke, TIA) occur after the carotid surgery procedure takes place2. How to preserve the flexibility of an open-celled stent while building in embolic protection? OUR SOLUTION: The CGuard EPS The only stent platform available with our patented Micr
Slide 8: OUR SOLUTION: CGuard Stent with Proprietary MicroNet Technology
OUR SOLUTION: CGuard™ Stent with Proprietary MicroNet™ Technology Mesh-covered stent offers superior plaque coverage when compared to conventional stents Conventional Open Cell Stent (15t GEN): CGuard Stent System (2"4 GEN): Larger allow inc Plaque protrusion risk Stents are covered in MicroNet to m
Slide 9: Stent Cell Sizes
m= Stent Cell Sizes ‘Area Comparison (mm?) i retetes : & WallStent™ [ACCULINK™ ] * Bench test results may nok necessary be nici of cnical performance, Sten images approximately at sale But nt exact INSPIREMD CONFIDENTIAL
Slide 10: A Picture is Worth a Thousand Words...
A Picture is Worth a Thousand Words... Surgical Endarterectomy INSPIREMD Stenting
Slide 11: Unmatched Foundational Data and Evidence
Unmatched Foundational Data and Evidence INSPIREMD
Slide 12: PMA Trial Design (C-GUARDIANS)
PMA Trial Design (C-GUARDIANS) Prospective, multicenter international single-arm clinical trial + Pivotal study objective: to evaluate the safety and efficacy of the CGuard™ Carotid Stent System in the treatment of carotid artery stenosis + Primary Endpoint: Composite of DSMI through 30 days or ipsi
Slide 13: C-GUARDIANS: 30-Day Safety Outcomes
C-GUARDIANS: 30-Day Safety Outcomes 30-Day Death/Stroke/MI (DSMI) rates, compared to other carotid trials IUARDIANS 30-day outcom: 30-day DSMI (multi Intention Per 8.30% to Treat Protocol? 30-day DSMI_| 0.95% (3)| 0.63% (2) pe tax 5.40% : 5.10% 4.80% Ea Death 0.32% (1) 0.0% (0) 350% 230% Stroke 0.95
Slide 14: C-GUARDIANS: 1-Year Safety and Effectiveness Outcomes
C-GUARDIANS: 1-Year Safety and Effectiveness Outcomes Composite event rate of 30-Day Death/Stroke/MI (DSM) or Ipsilateral stroke between days 31-365 CGUARDIANS 1-Year outcomes 30-day DSMI or Ipsilateral Stroke to 1-Year Intention to Treat _ Per Protocol? —— Primary Endpoint: 30-day Death, Stroke, or
Slide 15: Safety Comparison: InspireMD vs. Silk Road vs. Contego Medical
Safety Comparison: InspireMD vs. Silk Road vs. Contego Medical 30-day Major Adverse Events (DSMI) with independent adjudication. INSPIREMD SILKROAD? Corie edi (CccuARDIANS US. Pivotal Trial} | (__ ROADSTER US. Pivotal Trial] | (PERFORMANCE IUS. Pivotal Trial } Intent to Treat (n=316) Intent to Treat
Slide 16: CARMEN Meta-Analysis (112 Studies, 68K Patients)
CARMEN Meta-Analysis (112 Studies, 68K Patients)* = Improvements from second- generation stents (SGS) relative to first-generation stents (FGS), but important differences exist amongst the SGS = CGuard’s MicroNet drives improvement both in event reduction (due to improved scaffolding) and restenosis
Slide 17: Randomized DW-MRI Study Comparing CGuard and Acculink
Randomized DW-MRI Study Comparing CGuard and Acculink Demonstrates the Neuroprotective Effect of MicroNet™ Cerebral Embolic Lesions With Conventional Versus MicroNet-Covered Stent for Carotid freer Revaseuarzation (N ~ 100) Te hap o PsA war Guar on on WH 3 ty BW Randomized Controlled Study of MicroN
Slide 18: TCAR
TCAR INSPIREMD
Slide 19: Transcarotid Arterial Revascularization (TCAR): Direct Carotid Access with Reverse Flow
Transcarotid Arterial Revascularization (TCAR): Direct Carotid Access with Reverse Flow InspireMD combines SwitchGuard NPS with Best-in-Class CGuard Implant 4 Transient flow reversal combined with sustained embolic prevention in transervcalrevascularization of symptomatic and hghly-embeligenic caret
Slide 20: SwitchGuard NPS (TCAR)
SwitchGuard NPS (TCAR) ——tillllll 80CM CGUARDPpRIME es a sj SWITCH i@ GUARD INSPIREMD ( > TCAR Market Opportunii >2,800 TCAR-trained physicians in the U.S.t >25,000 TCAR procedures ($177M) performed in the U.S. in 2023, double- digit growth projected? InspireMD’s CGUARDIANS II TCAR trial anticipated
Slide 21: The Promise of TCAR with CGuard
The Promise of TCAR with CGuard DW MRI study of recently symptomatic patients- Professor Nacho Leal at LINC 2024 + “Transcarotid Flow Reversal and MicroNET Covered Stent for Carotid Revascularization in Recently Symptomatic Patients: A DW. MRI-Based Prospective Evaluation” » 15 recently-symptomatic
Slide 22: Corporate
Corporate INSPIREMD
Slide 23: Roadmap / Milestones
Roadmap / Milestones Key Value Drivers + SwitchGuard NPS Approval + Launch + FDA PMA Submission (Module Il il and IV) + CGuard Prime PMA Approval for CAS + Initiation of CGUARDIANS II (TCAR) study and TCAR * Scale US Operations + Acute Stroke EFS- Tandem Lesions + US. Commercial Launch + Approval Ch
Slide 24: Commercial Footprint: Over 50,000 systems sold
Commercial Footprint + Over 50,000 systems sold + Active selling in more than 30 countries + Average CAS Market share of 25% @5) Signed agreement with Chinese distributor. Working toward distribution Investigational Device Exemption (IDE) trial enrollment completed Q2 2023; potential PMA £ opportuni
Slide 25: Executive Leadership Team
Executive Leadership Team Deep industry experience and subject matter expertise 30+ years medical device + 20+ years cardiovascular : experience, NSPR since 2019 medical device experience, + Previous CEO/President of NSPR since 2023 ITAMAR Medical, Ovalum + Previous CCO of Nuvaira; VP_ + Vascular, P
Slide 26: Executive Leadership Team (continued)
Executive Leadership Team (continued) Deep industry experience and subject matter expertise Peter Ligotti Dr Patrick Verta Amir Kohen Cheryl Tal EVP and General Manager EVP Clinical & Medical Affairs SVP Finance & HR VP Quality & Regulatory Affairs + 30+ years medical device experience, joined NSPR
Slide 27: Scientific Advisory Board
Scientific Advisory Board (Multidisciplinary KOLs) 2 me Kenneth Rosenfield, M.D. Adnan H. Siddiqui, M.D. Ph.D Chris Metzger , M.D. Interventional Professor, Vice Chairman of the Medical Director Cardiologist Department of Neurosurgery Cardiologist iii Mass me Ne Neurosurgery Cleveland Clinic Brigham
Slide 28: Board of Directors
Board of Directors ‘Marvin L. Slosman President and CEO Paul Stuka Chairman ‘Michael Berman Director Thomas Kester Director Gary Roubin, M. Director Katie Arnold Director David Bonita, MD Board Observer INSPIREMD PhD. Mr. Slosman has over 30 years of experience in the medical device industry with fo
Slide 29: Robust Intellectual Property Portfolio
Robust Intellectual Property Portfolio Proprietary platform technology supported by IP Issued Pendii USA 19 6 Patent Rest of World 40 al7/ InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products IP Counsel Kigierand Associates, PA INSPIREMD
Slide 30: Transformational May 2023 Financing Up To $113.6 Million
Transformational May 2023 Financing Up To $113.6 Million To advance the company towards potential US approval and launch of CGuard EPS and other value-creating milestones * $42.2 million upfront funding * $71.4 million tied to the achievement of four milestones ($17.9 million each) each expiring upo
Slide 31: Summary Financials
Summary Financials June 11, 2024 NASDAQ Capital Markets NSPR Stock Price $2.68 Average 3 Month Volume 34.9K Shares Outstanding 25.1M Shares Outstanding with Prefunded Warrants 38.9M Market Capitalization with Prefunded Warrants $104.2M Cash Balance - March 31, 2024 $34.0M Debt $0M INSPIREMD
Slide 32: InspireMD
INSPIREMOD Nasdaq: NSPR